<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to the adult patient needing vascular access for chronic hemodialysis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to the adult patient needing vascular access for chronic hemodialysis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Approach to the adult patient needing vascular access for chronic hemodialysis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matthew J Oliver, MD, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rob R Quinn, MD, PhD, FRCPC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ellen D Dillavou, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H148185298"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The goal of chronic hemodialysis access is to provide repeated access to the circulation with minimal complications. Decisions surrounding the initial choice of chronic hemodialysis access are complex and should be to maximize the likelihood of providing a functional access within a reasonable period of time, minimizing complications during creation and access use, maximizing options for lifelong access, and taking into consideration patient preferences. </p><p>An overall approach for establishing vascular access in the patient needing chronic hemodialysis is reviewed. Creating an arteriovenous (AV) hemodialysis access (AV fistula, AV graft) and placement and management of hemodialysis catheters are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/1917.html" rel="external">"Arteriovenous fistula creation for hemodialysis and its complications"</a> and  <a class="medical medical_review" href="/z/d/html/14023.html" rel="external">"Arteriovenous graft creation for hemodialysis and its complications"</a> and  <a class="medical medical_review" href="/z/d/html/1843.html" rel="external">"Central venous catheters for acute and chronic hemodialysis access and their management"</a>.)</p><p class="headingAnchor" id="H3317589431"><span class="h1">CHRONIC HEMODIALYSIS ACCESS</span></p><p class="headingAnchor" id="H3713290568"><span class="h2">Types of access</span><span class="headingEndMark"> — </span>The three principal forms of chronic hemodialysis access are arteriovenous (AV) fistulas, AV grafts, and hemodialysis catheters [<a href="#rid1">1,2</a>]. </p><p>Hemodialysis access is most commonly attained using vessels in the upper extremities. The lower extremity is a less commonly used access site [<a href="#rid3">3-5</a>]. The upper chest can be used when extremity sites have been exhausted. Finally, central venous catheters can be inserted into the inferior vena cava via translumbar or transhepatic routes if all other locations have been exhausted [<a href="#rid6">6</a>]. </p><p class="headingAnchor" id="H1744365586"><span class="h3">Arteriovenous fistulas</span><span class="headingEndMark"> — </span>An AV fistula is a deliberate connection between a native artery and vein and is typically constructed with an end-to-side, vein-to-artery anastomosis. The most commonly used AV fistulas are created by anastomosing the radial artery to the cephalic vein (radiocephalic fistula) or by anastomosing the brachial artery to the cephalic vein (brachiocephalic fistula). Brachiobasilic fistulas are also commonly created by anastomosing the brachial artery to the basilic vein, but this fistula is located deeper in the medial aspect of the upper arm and requires superficialization and lateral transposition for use. (See  <a class="medical medical_review" href="/z/d/html/1917.html" rel="external">"Arteriovenous fistula creation for hemodialysis and its complications"</a>.)</p><p class="headingAnchor" id="H2012494269"><span class="h3">Arteriovenous grafts</span><span class="headingEndMark"> — </span>AV grafts are constructed by interposing graft material between an artery and vein. AV grafts are typically made of expanded polytetrafluoroethylene (ePTFE) and typically have a diameter of 6 mm (range, 4 to 8 mm). Allografts are also available as AV access conduits [<a href="#rid7">7</a>]. Common AV grafts include straight forearm (radial artery to cephalic vein), looped forearm (brachial artery to cephalic or brachial vein), straight upper arm (brachial artery to axillary vein), and looped upper arm (axillary artery to axillary vein). Early cannulation AV grafts are also available that can be used within one day of AV graft creation [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/14023.html" rel="external">"Arteriovenous graft creation for hemodialysis and its complications"</a>.) </p><p class="headingAnchor" id="H1800108550"><span class="h3">Central venous catheters</span><span class="headingEndMark"> — </span>Chronic hemodialysis catheters are tunneled, cuffed central venous access devices. They are dual-lumen catheters constructed from polyurethane, silicone, or silicone composites. The lumen size generally ranges from 10 to 16 French. They are normally inserted into the internal jugular vein and tunneled through a subcutaneous tract with a Dacron cuff positioned under the skin proximal to the exit site. (See  <a class="medical medical_review" href="/z/d/html/1843.html" rel="external">"Central venous catheters for acute and chronic hemodialysis access and their management"</a>.)</p><p class="headingAnchor" id="H2491975373"><span class="h2">General comparison</span><span class="headingEndMark"> — </span>Each type of vascular access has a unique set of risks and benefits. This section will focus on the differences that could affect decision making with respect to selection. Decision making should consider patient anatomy, ease of creation, ease of use, preservation of future access sites, risk of primary failure, expected patency, risk of complications during use, and patient preferences. </p><p class="headingAnchor" id="H3414954681"><span class="h3">Ease of creation</span><span class="headingEndMark"> — </span>Central venous catheters can be inserted in nearly all patients and are usually performed in interventional suites or special procedure rooms. Simple radiocephalic or brachiocephalic fistulas are typically created in the operating room with sedation under local anesthesia or regional nerve blocks. Studies have also described percutaneous fistula creation in the interventional suite, in the operating room, or in a procedure room using ultrasound alone [<a href="#rid9">9-11</a>]. Brachiobasilic fistulas and AV grafts are more extensive procedures and may require regional nerve blocks or a general anesthetic. Regional nerve block anesthesia provides a safe, comfortable anesthetic, and the associated vasodilation was shown in a randomized trial to improve the primary patency defined as thrill or bruit in the absence of any additional intervention to reestablish function of those fistulas [<a href="#rid12">12</a>]. Most of the failures in the local anesthetic group were loss of immediate patency at discharge from hospital, and there was no difference in functional patency at three months. </p><p>Some patients deemed to be at high surgical risk may not be candidates for more extensive surgery. </p><p class="headingAnchor" id="H2561730606"><span class="h3">Primary failure</span><span class="headingEndMark"> — </span>The risk of primary failure of AV fistulas is highly variable and has ranged from 47 to 60 percent in randomized trials, but the published rates depend heavily on the definition of failure [<a href="#rid13">13,14</a>]. The Hemodialysis Fistula Maturation Study, which was a prospective observational study, reported a risk of primary failure of 33 percent [<a href="#rid15">15</a>]. A meta-analysis that included 43 studies reported a lower rate at 23 percent [<a href="#rid16">16</a>]. To achieve a functional AV fistula, patients should be educated that additional interventions may be needed given the high risk of primary failure. </p><p>AV grafts have a lower risk of primary failure. In a study of 1012 AV fistulas and 128 AV grafts, the risk of primary failure for AV grafts was one half the risk of AV fistulas (19 versus 40 percent) [<a href="#rid17">17</a>]. A comparison of brachiocephalic fistulas, brachiobasilic fistulas, and upper arm AV grafts reported primary failure rates of 32, 21, and 15 percent, respectively [<a href="#rid18">18</a>]. In a retrospective study of 16,463 Medicare patients in the United States, repeat AV fistula/graft creation was required within one year for 27 percent among patients with AV fistulas compared with 17 percent among those with AV grafts [<a href="#rid19">19</a>]. It should be noted the risk of primary failure may be reduced by careful imaging of vessels to ensure adequate vessels for AV fistula creation [<a href="#rid20">20,21</a>]. </p><p>Primary failure (or malfunction) of central venous catheters is rare, although they may fail immediately after insertion due to kinking or poor positioning. (See  <a class="medical medical_review" href="/z/d/html/1906.html" rel="external">"Malfunction of chronic hemodialysis catheters"</a>.)</p><p class="headingAnchor" id="H1494683699"><span class="h3">Cumulative patency</span><span class="headingEndMark"> — </span>Cumulative (secondary) patency, either including or excluding primary failure, has been reported. When primary failure of AV fistulas is accounted for, cumulative patency of AV fistulas and AV grafts is similar up to three years from creation. As an example, in a review of 1140 hemodialysis patients with AV fistulas or AV grafts comprising a mixture of upper arm and lower arm locations, the cumulative patency did not differ significantly between AV fistulas and AV grafts as a first AV access (median 7.4 versus 15.0 months, respectively [hazard ratio 0.99, 95% CI 0.79-1.23]) [<a href="#rid17">17</a>]. A multicenter study from the Netherlands reported similar three-year cumulative patency rates (including primary failure) for radiocephalic fistulas (64 percent), brachiocephalic fistulas (75 percent), and upper arm (75 percent) [<a href="#rid22">22</a>]. Similar cumulative patencies were also found when brachiobasilic fistulas were compared with brachiocephalic fistulas and upper arms grafts [<a href="#rid23">23</a>]. In a decision analysis, AV fistulas had less benefit compared with AV grafts among older patients, particularly women with diabetes, reflecting their lower AV fistula success rates and lower life expectancy [<a href="#rid24">24</a>]. </p><p class="headingAnchor" id="H3952717258"><span class="h3">Complications</span><span class="headingEndMark"> — </span>AV fistulas, once matured, are associated with the lowest complication rates, although some may require angioplasty to facilitate maturation or repeated angioplasty to maintain blood flow. Comparatively speaking, AV grafts have a higher risk of long-term complications, particularly stenosis at the venous anastomosis or thrombosis requiring repeated interventions. AV grafts can also be complicated by infection, whereas AV fistulas rarely have infections. AV grafts may have higher rates of initial dialysis-related steal syndrome. (See  <a class="medical medical_review" href="/z/d/html/1917.html" rel="external">"Arteriovenous fistula creation for hemodialysis and its complications"</a> and  <a class="medical medical_review" href="/z/d/html/14023.html" rel="external">"Arteriovenous graft creation for hemodialysis and its complications"</a> and  <a class="medical medical_review" href="/z/d/html/113760.html" rel="external">"Hemodialysis access-induced distal ischemia"</a>.)</p><p>Central venous catheters have a high risk of complications after initial use, including low blood flow/thrombosis, mechanical complications (extruded cuffs, cracked lumens, catheters being pulled out accidentally), infectious complications (exit site/tunnel infections and bloodstream infections), and damage to central veins. Catheters often require exchanges and replacements to maintain access. In a retrospective review reporting complications that resulted in a procedure, hospitalization, or death, the cumulative risk of any catheter-related complications was 30 percent at one year and 38 percent at two years [<a href="#rid25">25</a>]. The one-year risk of bacteremia was 9 percent, and this was responsible for 72 percent of catheter-related hospitalizations. Symptomatic central venous stenosis or thrombosis requiring intervention occurred in 1.5 percent of patients, and blood flow restriction was responsible for 35 percent of procedures but did not result in any hospitalizations. (See  <a class="medical medical_review" href="/z/d/html/1906.html" rel="external">"Malfunction of chronic hemodialysis catheters"</a> and  <a class="medical medical_review" href="/z/d/html/1966.html" rel="external">"Tunneled hemodialysis catheter-related bloodstream infection (CRBSI): Management and prevention"</a> and  <a class="medical medical_review" href="/z/d/html/1913.html" rel="external">"Central vein obstruction associated with upper extremity hemodialysis access"</a>.) </p><p class="headingAnchor" id="H3674125971"><span class="h1">STRATEGY FOR LIFELONG HEMODIALYSIS ACCESS</span><span class="headingEndMark"> — </span>The 2019 National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guideline for Vascular Access Update states that care decisions surrounding hemodialysis access are often complex and should be individualized to promote patient-centered care using an interdisciplinary team composed of experienced nurses, nephrologists, radiologists, and vascular surgeons [<a href="#rid26">26</a>]. A lifelong access strategy in patients with end-stage kidney disease (ie, ESKD Life-Plan) begins with preserving veins for potential future access; carefully evaluating patients for initial arteriovenous (AV) access if hemodialysis is selected for renal replacement therapy; properly accessing, maintaining, and monitoring the access; and timely management of problems if they arise according to the patient's defined contingency and succession access plans [<a href="#rid26">26</a>]. The ESKD Life-Plan should be reviewed annually. </p><p class="headingAnchor" id="H1370036026"><span class="h2">Patient-centered approach</span><span class="headingEndMark"> — </span>Historically, AV fistulas were strongly promoted by guidelines because of their association with lower mortality, lower complication rates, and lower cost. These guidelines included the 2006 National Kidney Foundation Kidney Disease Outcomes Quality Initiative (updated in 2019 to promote a patient-centered approach [<a href="#rid26">26</a>]) [<a href="#rid27">27</a>], the Canadian Society of Nephrology (2006) [<a href="#rid28">28</a>], European Renal Best Practice (2007) [<a href="#rid29">29</a>], and Kidney Health Australia – Caring for Australasians with Renal Impairment (KHA-CARI; 2012) [<a href="#rid30">30</a>]. Furthermore, reimbursement has been tied to AV fistula use, particularly in the United States. However, a number of observations challenged the "fistula first" approach: </p><p class="bulletIndent1"><span class="glyph">●</span>The risk of primary AV fistula failure was observed to be approximately 50 percent in high-quality randomized studies [<a href="#rid13">13,14</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The benefit of AV fistulas was attenuated in higher risk populations. As an example, a study of 115,425 incident hemodialysis patients 67 years or older derived from the United States Renal Data System with linked Medicare claims did not detect a significant mortality difference between those patients who received a AV graft as the first access placed and those patients who received an AV fistula (hazard ratio [HR] 1.05, 95% CI 1.00-1.11) [<a href="#rid31">31</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of selection bias in studies showing benefit for AV fistulas was very high. As a consequence, it was not clear if the better outcomes observed in patients using AV fistulas for vascular access were due to choice of vascular access or the fact that patients treated with AV fistulas were healthier and had a better prognosis [<a href="#rid32">32</a>]. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a retrospective cohort study of 2300 incident hemodialysis patients at five Canadian dialysis programs, a predialysis AV fistula creation was associated with a lower risk of all-cause mortality in patients under 65 years of age (HR 0.49, 95% CI 0.29-0.82) and in the first two years of follow-up in those age 65 years and older, but a higher risk thereafter (HR 0 to 24 months: 0.60, 95% CI 0.43-0.84; HR &gt;24 months: 1.83, 95% CI 1.25-2.67) [<a href="#rid33">33</a>]. Importantly, only 2.3 percent of deaths were access related. When the authors compared outcomes between those who used their AV fistulas and those who used a catheter because their AV fistula attempts failed, there was no difference in mortality between the two groups. In other words, patients who were deemed fit for an AV fistula attempt had a survival advantage, independent of whether or not they ever used the AV fistula for hemodialysis. This again reinforces the idea that the excess mortality observed in hemodialysis patients treated with catheters may be the result of residual confounding, unmeasured comorbidity, or treatment selection bias, rather than an effect of the access itself. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Similarly, a study from the United States of 90,517 patients who initiated dialysis with a catheter or AV fistula found a significant mortality benefit among those treated with AV fistulas (HR 0.50, 95% CI 0.48-0.52). However, the mortality rates were also significantly attenuated among those who had a failed AV fistula attempt and dialyzed with a catheter (43 percent in total) when compared with the catheter-only group (HR 0.66, 95% CI 0.64-0.68) [<a href="#rid34">34</a>]. The authors concluded that patient factors likely explain at least two-thirds of the observed difference in mortality in patients treated with an AV fistula.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A limited number of randomized trials are available comparing the different types of AV access. These include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Brachiobasilic fistula versus forearm loop graft — A multicenter study randomly assigned 105 patients with failed AV fistulas or inadequate vessels for radiocephalic or brachiocephalic fistulas to either a brachiobasilic fistula or loop forearm AV graft [<a href="#rid35">35</a>]. Fifty-two percent of patients in the brachiobasilic group and 15 percent of the AV graft group had previously failed an AV fistula. A radial artery and/or cephalic vein diameter of less than 2 mm at the wrist and less than 3 mm at the elbow was defined as unsuitable for the creation of a radiocephalic fistula or brachiocephalic fistula. Compared with the AV graft group, the brachiobasilic group had significantly higher primary patency (46 versus 22 percent) and primary assisted patency (87 versus 71 percent) at one year. Another small trial randomly assigned 57 patients to creation of a brachiobasilic fistula or an AV graft using a collagen-polyester composite material [<a href="#rid36">36</a>]. While patients in the brachiobasilic fistula group had a longer time to cannulation (43 versus 27 days), they had a higher primary patency at one year (52 versus 32 percent), in part because of a lower risk of thrombosis (12 versus 31 episodes).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Distal AV fistula versus forearm loop graft — A trial that randomly assigned 182 patients with less-than-ideal vessels for radiocephalic fistulas (radial artery between 1 and 2 mm and/or a cephalic vein of 1.6 mm or less) to either an attempt at a radiocephalic fistula or a forearm loop graft found that the AV graft group had higher primary (48 versus 33 percent) and secondary (79 versus 52 percent) patency rates at one year [<a href="#rid37">37</a>].</p><p></p><p>These observations provided a fresh and critical look at the assumptions that underpinned the promotion of AV fistulas and further contributed to equipoise around this issue. More randomized comparisons of different forms of access are needed. For example, a pilot randomized trial of AV fistula creation in patients who start dialysis with a central venous catheter is underway in Canada to address the feasibility of answering this question in a larger trial (Clinicaltrials.gov identifier: NCT02675569) [<a href="#rid38">38</a>]. In the Netherlands, a randomized trial comparing AV grafts or central venous catheters with AV fistulas is underway [<a href="#rid39">39</a>]. </p><p>The updated KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update has adopted a patient-centered approach, acknowledging their recommendations are based on expert opinion given the lack of high-quality evidence [<a href="#rid26">26</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>KDOQI considers it reasonable to have an AV access (AV fistula or AV graft) in a patient requiring hemodialysis, when consistent with their ESKD Life-Plan and overall goals of care. (See <a class="local">'AV fistula appropriateness'</a> below and <a class="local">'AV graft appropriateness'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>KDOQI considers it reasonable in certain clinical circumstances to use tunneled central venous catheters for short- or long-term access. (See <a class="local">'Catheter appropriateness'</a> below.)</p><p></p><p>In addition to the recognition of the importance of patient preference, the guidelines acknowledge the evidence to support the lower risk of bacteremia and bacteremia-related hospitalization in those treated with AV fistulas is of low quality. They also state that there is inadequate evidence to claim AV fistula use results in a lower risk of overall infection, hospitalization, or mortality with AV fistula use – a major departure from prior guidelines.</p><p class="headingAnchor" id="H1941558068"><span class="h2">Preservation of veins</span><span class="headingEndMark"> — </span>Preservation of peripheral veins and the venous circuit back to the heart is an important component of vascular access planning [<a href="#rid40">40</a>]. It is important to avoid iatrogenic trauma to the venous circulation due to phlebotomy or intravenous access in patients who are at risk for developing end-stage kidney disease or who are already receiving renal replacement therapy of any type. Most experts agree that education regarding vein preservation should begin in individuals with stage 4 or 5 chronic kidney disease and strategies should be implemented to avoid unnecessary trauma to the venous circulation [<a href="#rid27">27,41</a>]. </p><p>Central venous access should be via a tunneled, internal jugular catheter, while subclavian catheters and peripherally inserted central catheters (PICCs) should be avoided, particularly in the nondominant arm, due to the risk of central venous stenosis and thrombosis. Venous access and phlebotomy should be avoided in the veins of the nondominant arm except in the dorsum of the hand where practical. In patients with pacemakers or previous axillary node dissections, efforts to protect the contralateral arm should be taken. (See  <a class="medical medical_review" href="/z/d/html/115957.html" rel="external">"Central venous access: Device and site selection in adults", section on 'General patient considerations'</a>.)</p><p class="headingAnchor" id="H2848114640"><span class="h2">Initial access</span><span class="headingEndMark"> — </span>A rational strategy for initial (incident) access selection for the individual patient should take into account not only guideline recommendations and local performance targets but the likelihood of success, the expected benefits of one approach versus another, and patient preferences [<a href="#rid1">1,2</a>]. Whether an AV fistula is the best initial access for all patients remains debated. (See <a class="local">'General comparison'</a> above and <a class="local">'Patient-centered approach'</a> above.)</p><p>All predialysis patients with an expected start of hemodialysis within one year and patients who have initiated hemodialysis with a catheter should be evaluated to determine eligibility for AV access creation [<a href="#rid27">27,42</a>]. Exceptions include patients with limited life expectancy (eg, metastatic cancer or severe heart failure) or patients with a very short expected duration of hemodialysis (eg, pending living-related transplant). (See  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Preparation for and initiation of kidney replacement therapy'</a> and  <a class="medical medical_review" href="/z/d/html/1844.html" rel="external">"Dialysis modality and patient outcome"</a>.)</p><p>The duration of hemodialysis catheter use should be minimized to avoid complications, particularly central vein stenosis, which can prevent future AV access success. Patients using catheters should be informed about the potential risks of continued use of their catheter. Those without complications may be reluctant to change their access, but these patients should be approached again if they have catheter complications. Some patients may not consent to AV access creation in spite of being informed of the benefits of AV access creation and the risk of hemodialysis catheter use.</p><p class="headingAnchor" id="H2217313065"><span class="h3">AV fistula appropriateness</span><span class="headingEndMark"> — </span>As a first step, the anatomic and clinical appropriateness of an AV fistula needs to be determined. The anatomic evaluation includes physical examination and may include vascular mapping, typically using ultrasound, to measure the characteristics (eg, diameter, depth) of the available vessels and screen for stenosis or thrombosis. The KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update recommends selective preoperative ultrasound in patients at high risk for AV access failure [<a href="#rid26">26</a>]. While there is no minimum vessel diameter, arteries and veins less than 2 mm should undergo careful evaluation for feasibility and quality prior to creating an AV fistula. (See  <a class="medical medical_review" href="/z/d/html/110008.html" rel="external">"Patient evaluation prior to placement of hemodialysis arteriovenous access"</a> and  <a class="medical medical_review" href="/z/d/html/1917.html" rel="external">"Arteriovenous fistula creation for hemodialysis and its complications", section on 'Evaluation and planning'</a>.) </p><p>Multiple studies have demonstrated risk factors for AV fistula failure, including the use of predictive risk scores [<a href="#rid43">43</a>]. In a study that applied RAND/UCLA appropriateness methodology to 3816 AV fistula and AV graft scenarios, younger age, larger outflow vein diameter, normal or obese body mass index (versus morbidly obese), larger inflow artery diameter, and higher patient functional status were associated with appropriateness of AV fistula creation by a panel of vascular access experts [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/z/d/html/113929.html" rel="external">"Risk factors for hemodialysis arteriovenous fistula failure"</a>.)</p><p class="headingAnchor" id="H2429142019"><span class="h3">AV graft appropriateness</span><span class="headingEndMark"> — </span>If the expected duration of dialysis is less than two years, and an AV fistula is not possible, then an AV graft should be considered. Early-use AV grafts should be considered to expedite catheter removal as this may decrease catheter-related complications [<a href="#rid26">26,44</a>]. (See  <a class="medical medical_review" href="/z/d/html/110008.html" rel="external">"Patient evaluation prior to placement of hemodialysis arteriovenous access"</a> and  <a class="medical medical_review" href="/z/d/html/14023.html" rel="external">"Arteriovenous graft creation for hemodialysis and its complications", section on 'Evaluation and planning'</a>.)</p><p>In a review of over 66,000 dialysis-dependent patients 66 years or older, the incidence of repeat AV fistula/graft creation and tunneled catheter placement was significantly lower in the first 12 months after index AV graft creation compared with AV fistulas (33.7 versus 44.4 percent) [<a href="#rid19">19</a>]. However, AV fistulas were associated with significantly reduced mortality compared with AV grafts (28.2 versus 29.9 percent). </p><p>In the RAND/UCLA study, factors associated with appropriateness for an AV graft included older age and smaller vein size [<a href="#rid1">1,2</a>]. There was no association between sex, diabetes, coronary artery disease, body mass index, or functional status and appropriateness of either a forearm loop graft or upper arm graft.</p><p class="headingAnchor" id="H1516117485"><span class="h3">Catheter appropriateness</span><span class="headingEndMark"> — </span>Some patients cannot achieve AV access and may need to be managed with a central catheter either in the short term or long term. (See  <a class="medical medical_review" href="/z/d/html/1843.html" rel="external">"Central venous catheters for acute and chronic hemodialysis access and their management"</a>.)</p><p>Appropriate use of a hemodialysis catheter in the short or long term include [<a href="#rid26">26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Short-term duration: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>AV fistula or AV graft created, but not ready for use, and dialysis is required.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute transplant rejection or other complications requiring dialysis. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Peritoneal dialysis patient with complications that requires time-limited peritoneal rest or resolution of complication (eg, exit site leak).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patient has a living donor transplant confirmed with an operation date soon (eg, &lt;90 days) but requires dialysis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>AV fistula or AV graft complication such as major infiltration injury or cellulitis that results in temporary nonuse until problem is resolved. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term or indefinite duration: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Multiple prior failed AV accesses with no available options (see anatomic restrictions below).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Valid patient preference, whereby use of an AV access would severely limit quality of life or achievement of life goals and after the patient has been properly informed of patient-specific risks and benefits of other potential and reasonable access options for that patient (if available).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Limited life expectancy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Absence of AV access creation options due to a combination of inflow artery and outflow vein problems (eg, severe arterial occlusive disease, noncorrectable central venous outflow occlusion) or in those with prohibitively diminutive vessels.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Special medical circumstances. </p><p></p><p class="headingAnchor" id="H1024989250"><span class="h2">Access maintenance</span><span class="headingEndMark"> — </span>Proper routine care and maintenance of the access is important to minimizing injury that can lead to dysfunction and thrombosis. This includes the following measures, which are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/112108.html" rel="external">"Overview of hemodialysis arteriovenous fistula maintenance and thrombosis prevention"</a> and  <a class="medical medical_review" href="/z/d/html/1950.html" rel="external">"Overview of hemodialysis arteriovenous graft maintenance and thrombosis prevention"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Sterile precautions when accessing </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Proper cannulation and decannulation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Proper care and routine monitoring by the patient at home </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring clearance rates and access pressures during hemodialysis to identify access dysfunction and intervening on stenoses prior to access thrombosis</p><p></p><p>Similarly, proper care and maintenance of hemodialysis catheters will reduce the risk for complications, such as infection, catheter thrombosis, and catheter-related thoracic central vein obstruction. (See  <a class="medical medical_review" href="/z/d/html/1906.html" rel="external">"Malfunction of chronic hemodialysis catheters"</a> and  <a class="medical medical_review" href="/z/d/html/1913.html" rel="external">"Central vein obstruction associated with upper extremity hemodialysis access"</a> and  <a class="medical medical_review" href="/z/d/html/1843.html" rel="external">"Central venous catheters for acute and chronic hemodialysis access and their management", section on 'Routine care and access for hemodialysis'</a>.)</p><p class="headingAnchor" id="H3168739655"><span class="h2">Access following failed AV fistula or graft</span><span class="headingEndMark"> — </span>For patients who develop AV access dysfunction, the individualized ESKD Life-Plan should include plans to salvage the access and if attempts to salvage the access are not successful, plans for future AV access. The vascular evaluation and mapping for determining the appropriateness of a contingency or successive AV access is similar to that undertaken for initial AV access creation [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/96402.html" rel="external">"Primary failure of the hemodialysis arteriovenous fistula"</a> and  <a class="medical medical_review" href="/z/d/html/1957.html" rel="external">"Failure of the mature hemodialysis arteriovenous fistula"</a> and  <a class="medical medical_review" href="/z/d/html/1971.html" rel="external">"Hemodialysis arteriovenous graft dysfunction and failure"</a> and  <a class="medical medical_review" href="/z/d/html/1835.html" rel="external">"Hemodialysis access following a failed arteriovenous access"</a>.)</p><p>Some patients will have exhausted options for creation of a secondary AV access and will necessarily require a hemodialysis catheter. (See <a class="local">'Catheter appropriateness'</a> above.)</p><p class="headingAnchor" id="H3656320749"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112932.html" rel="external">"Society guideline links: Dialysis"</a>.)</p><p class="headingAnchor" id="H3131417386"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16270.html" rel="external">"Patient education: Preparing for hemodialysis (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16269.html" rel="external">"Patient education: Hemodialysis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H4070203034"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The three principal forms of chronic hemodialysis vascular access are arteriovenous (AV) fistulas, AV grafts, and hemodialysis catheters placed into a central vein. AV fistulas and AV grafts are deliberate connections between a native artery and vein. Each of these options has advantages and disadvantages. (See <a class="local">'Chronic hemodialysis access'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Care decisions surrounding hemodialysis access are often complex and should be individualized to promote patient-centered care using an interdisciplinary team composed of experienced nurses, nephrologists, radiologists, and vascular surgeons. (See <a class="local">'Strategy for lifelong hemodialysis access'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A lifelong access strategy in patients with chronic kidney disease begins with preserving veins for potential future access; carefully evaluating patients for initial AV access if hemodialysis is selected for renal replacement therapy; properly accessing, maintaining, and monitoring the access; and timely management of problems if they arise. (See <a class="local">'Strategy for lifelong hemodialysis access'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients without contraindications to AV access, AV fistulas have been strongly promoted in the past; however, under certain circumstances, AV graft placement may be equally appropriate, or more appropriate for initial AV access. For some patients, hemodialysis catheters may be an appropriate hemodialysis access in the short or long term. (See <a class="local">'Initial access'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The justification for a "fistula first" approach has been a consistent association of AV fistula use with lower morbidity and mortality in observational studies. It is important to recognize the high risk of bias in these studies. It is not clear whether the better outcomes observed in patients using AV fistulas for initial vascular access were due to the choice of vascular access or that patients selected for AV fistulas were healthier and had a better prognosis. Later large observational studies support this concept, but ideally a randomized comparison of different types of hemodialysis access is needed to better inform decision making in clinical practice. (See <a class="local">'Patient-centered approach'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Woo K, Ulloa J, Allon M, et al. Establishing patient-specific criteria for selecting the optimal upper extremity vascular access procedure. J Vasc Surg 2017; 65:1089.</a></li><li><a class="nounderline abstract_t">Lok CE, Davidson I. Optimal choice of dialysis access for chronic kidney disease patients: developing a life plan for dialysis access. Semin Nephrol 2012; 32:530.</a></li><li><a class="nounderline abstract_t">Miller CD, Robbin ML, Barker J, Allon M. Comparison of arteriovenous grafts in the thigh and upper extremities in hemodialysis patients. J Am Soc Nephrol 2003; 14:2942.</a></li><li><a class="nounderline abstract_t">Ram SJ, Sachdeva BA, Caldito GC, et al. Thigh grafts contribute significantly to patients' time on dialysis. Clin J Am Soc Nephrol 2010; 5:1229.</a></li><li><a class="nounderline abstract_t">Gradman WS, Laub J, Cohen W. Femoral vein transposition for arteriovenous hemodialysis access: improved patient selection and intraoperative measures reduce postoperative ischemia. J Vasc Surg 2005; 41:279.</a></li><li><a class="nounderline abstract_t">Liu F, Bennett S, Arrigain S, et al. Patency and Complications of Translumbar Dialysis Catheters. Semin Dial 2015; 28:E41.</a></li><li><a class="nounderline abstract_t">Lawson JH, Glickman MH, Ilzecki M, et al. Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials. Lancet 2016; 387:2026.</a></li><li><a class="nounderline abstract_t">Aitken E, Thomson P, Bainbridge L, et al. A randomized controlled trial and cost-effectiveness analysis of early cannulation arteriovenous grafts versus tunneled central venous catheters in patients requiring urgent vascular access for hemodialysis. J Vasc Surg 2017; 65:766.</a></li><li><a class="nounderline abstract_t">Hull JE, Jennings WC, Cooper RI, et al. The Pivotal Multicenter Trial of Ultrasound-Guided Percutaneous Arteriovenous Fistula Creation for Hemodialysis Access. J Vasc Interv Radiol 2018; 29:149.</a></li><li><a class="nounderline abstract_t">Mallios A, Jennings WC, Boura B, et al. Early results of percutaneous arteriovenous fistula creation with the Ellipsys Vascular Access System. J Vasc Surg 2018; 68:1150.</a></li><li><a class="nounderline abstract_t">Lok CE, Rajan DK, Clement J, et al. Endovascular Proximal Forearm Arteriovenous Fistula for Hemodialysis Access: Results of the Prospective, Multicenter Novel Endovascular Access Trial (NEAT). Am J Kidney Dis 2017; 70:486.</a></li><li><a class="nounderline abstract_t">Aitken E, Jackson A, Kearns R, et al. Effect of regional versus local anaesthesia on outcome after arteriovenous fistula creation: a randomised controlled trial. Lancet 2016; 388:1067.</a></li><li><a class="nounderline abstract_t">Irish AB, Viecelli AK, Hawley CM, et al. Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis: A Randomized Clinical Trial. JAMA Intern Med 2017; 177:184.</a></li><li><a class="nounderline abstract_t">Dember LM, Beck GJ, Allon M, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA 2008; 299:2164.</a></li><li><a class="nounderline abstract_t">Cheung AK, Imrey PB, Alpers CE, et al. Intimal Hyperplasia, Stenosis, and Arteriovenous Fistula Maturation Failure in the Hemodialysis Fistula Maturation Study. J Am Soc Nephrol 2017; 28:3005.</a></li><li><a class="nounderline abstract_t">Al-Jaishi AA, Oliver MJ, Thomas SM, et al. Patency rates of the arteriovenous fistula for hemodialysis: a systematic review and meta-analysis. Am J Kidney Dis 2014; 63:464.</a></li><li><a class="nounderline abstract_t">Lok CE, Sontrop JM, Tomlinson G, et al. Cumulative patency of contemporary fistulas versus grafts (2000-2010). Clin J Am Soc Nephrol 2013; 8:810.</a></li><li><a class="nounderline abstract_t">Oliver MJ, McCann RL, Indridason OS, et al. Comparison of transposed brachiobasilic fistulas to upper arm grafts and brachiocephalic fistulas. Kidney Int 2001; 60:1532.</a></li><li><a class="nounderline abstract_t">Woo K, Goldman DP, Romley JA. Early Failure of Dialysis Access among the Elderly in the Era of Fistula First. Clin J Am Soc Nephrol 2015; 10:1791.</a></li><li><a class="nounderline abstract_t">Wong CS, McNicholas N, Healy D, et al. A systematic review of preoperative duplex ultrasonography and arteriovenous fistula formation. J Vasc Surg 2013; 57:1129.</a></li><li><a class="nounderline abstract_t">Allon M, Lockhart ME, Lilly RZ, et al. Effect of preoperative sonographic mapping on vascular access outcomes in hemodialysis patients. Kidney Int 2001; 60:2013.</a></li><li><a class="nounderline abstract_t">Voorzaat BM, Janmaat CJ, van der Bogt KEA, et al. Patency Outcomes of Arteriovenous Fistulas and Grafts for Hemodialysis Access: A Trade-Off between Nonmaturation and Long-Term Complications. Kidney360 2020; 1:916.</a></li><li><a class="nounderline abstract_t">Maya ID, O'Neal JC, Young CJ, et al. Outcomes of brachiocephalic fistulas, transposed brachiobasilic fistulas, and upper arm grafts. Clin J Am Soc Nephrol 2009; 4:86.</a></li><li><a class="nounderline abstract_t">Drew DA, Lok CE, Cohen JT, et al. Vascular access choice in incident hemodialysis patients: a decision analysis. J Am Soc Nephrol 2015; 26:183.</a></li><li><a class="nounderline abstract_t">Poinen K, Quinn RR, Clarke A, et al. Complications From Tunneled Hemodialysis Catheters: A Canadian Observational Cohort Study. Am J Kidney Dis 2019; 73:467.</a></li><li><a class="nounderline abstract_t">Lok CE, Huber TS, Lee T, et al. KDOQI Vascular Access Guidelines Work Group. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis 2020; 75:S1.</a></li><li><a class="nounderline abstract_t">Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006; 48 Suppl 1:S2.</a></li><li><a class="nounderline abstract_t">Jindal K, Chan CT, Deziel C, et al. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 2006; 17:S1.</a></li><li><a class="nounderline abstract_t">Tordoir J, Canaud B, Haage P, et al. EBPG on Vascular Access. Nephrol Dial Transplant 2007; 22 Suppl 2:ii88.</a></li><li><a class="nounderline abstract_t">Polkinghorne KR, Chin GK, MacGinley RJ, et al. KHA-CARI Guideline: vascular access - central venous catheters, arteriovenous fistulae and arteriovenous grafts. Nephrology (Carlton) 2013; 18:701.</a></li><li><a class="nounderline abstract_t">DeSilva RN, Patibandla BK, Vin Y, et al. Fistula first is not always the best strategy for the elderly. J Am Soc Nephrol 2013; 24:1297.</a></li><li><a class="nounderline abstract_t">Ravani P, Palmer SC, Oliver MJ, et al. Associations between hemodialysis access type and clinical outcomes: a systematic review. J Am Soc Nephrol 2013; 24:465.</a></li><li><a class="nounderline abstract_t">Quinn RR, Oliver MJ, Devoe D, et al. The Effect of Predialysis Fistula Attempt on Risk of All-Cause and Access-Related Death. J Am Soc Nephrol 2017; 28:613.</a></li><li><a class="nounderline abstract_t">Brown RS, Patibandla BK, Goldfarb-Rumyantzev AS. The Survival Benefit of "Fistula First, Catheter Last" in Hemodialysis Is Primarily Due to Patient Factors. J Am Soc Nephrol 2017; 28:645.</a></li><li><a class="nounderline abstract_t">Keuter XH, De Smet AA, Kessels AG, et al. A randomized multicenter study of the outcome of brachial-basilic arteriovenous fistula and prosthetic brachial-antecubital forearm loop as vascular access for hemodialysis. J Vasc Surg 2008; 47:395.</a></li><li><a class="nounderline abstract_t">Morosetti M, Cipriani S, Dominijanni S, et al. Basilic vein transposition versus biosynthetic prosthesis as vascular access for hemodialysis. J Vasc Surg 2011; 54:1713.</a></li><li><a class="nounderline abstract_t">Rooijens PP, Burgmans JP, Yo TI, et al. Autogenous radial-cephalic or prosthetic brachial-antecubital forearm loop AVF in patients with compromised vessels? A randomized, multicenter study of the patency of primary hemodialysis access. J Vasc Surg 2005; 42:481.</a></li><li><a class="nounderline abstract_t">Quinn R, Ravani P, ACCESS HD Investigators. ACCESS HD pilot: A randomised feasibility trial Comparing Catheters with fistulas in Elderly patientS Starting haemodialysis. BMJ Open 2016; 6:e013081.</a></li><li><a class="nounderline abstract_t">Heggen BD, Ramspek CL, van der Bogt KEA, et al. Optimising Access Surgery in Senior Haemodialysis Patients (OASIS): study protocol for a multicentre randomised controlled trial. BMJ Open 2022; 12:e053108.</a></li><li><a class="nounderline abstract_t">Vachharajani TJ, Hassanein M, Liaqat A, Haddad N. Vessel Preservation in Chronic Kidney Disease. Adv Chronic Kidney Dis 2020; 27:177.</a></li><li><a class="nounderline abstract_t">Hoggard J, Saad T, Schon D, et al. Guidelines for venous access in patients with chronic kidney disease. A Position Statement from the American Society of Diagnostic and Interventional Nephrology, Clinical Practice Committee and the Association for Vascular Access. Semin Dial 2008; 21:186.</a></li><li><a class="nounderline abstract_t">Sidawy AN, Spergel LM, Besarab A, et al. The Society for Vascular Surgery: clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access. J Vasc Surg 2008; 48:2S.</a></li><li><a class="nounderline abstract_t">Lok CE, Allon M, Moist L, et al. Risk equation determining unsuccessful cannulation events and failure to maturation in arteriovenous fistulas (REDUCE FTM I). J Am Soc Nephrol 2006; 17:3204.</a></li><li><a class="nounderline abstract_t">Wagner JK, Dillavou E, Nag U, et al. Immediate-access grafts provide comparable patency to standard grafts, with fewer reinterventions and catheter-related complications. J Vasc Surg 2019; 69:883.</a></li></ol></div><div id="topicVersionRevision">Topic 115151 Version 11.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28222990" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Establishing patient-specific criteria for selecting the optimal upper extremity vascular access procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23217332" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Optimal choice of dialysis access for chronic kidney disease patients: developing a life plan for dialysis access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14569105" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Comparison of arteriovenous grafts in the thigh and upper extremities in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20413439" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Thigh grafts contribute significantly to patients' time on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15768010" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Femoral vein transposition for arteriovenous hemodialysis access: improved patient selection and intraoperative measures reduce postoperative ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25800550" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Patency and Complications of Translumbar Dialysis Catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27203778" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28236919" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A randomized controlled trial and cost-effectiveness analysis of early cannulation arteriovenous grafts versus tunneled central venous catheters in patients requiring urgent vascular access for hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29275056" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The Pivotal Multicenter Trial of Ultrasound-Guided Percutaneous Arteriovenous Fistula Creation for Hemodialysis Access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29680297" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Early results of percutaneous arteriovenous fistula creation with the Ellipsys Vascular Access System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28624422" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Endovascular Proximal Forearm Arteriovenous Fistula for Hemodialysis Access: Results of the Prospective, Multicenter Novel Endovascular Access Trial (NEAT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27492881" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of regional versus local anaesthesia on outcome after arteriovenous fistula creation: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28055065" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18477783" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28710091" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Intimal Hyperplasia, Stenosis, and Arteriovenous Fistula Maturation Failure in the Hemodialysis Fistula Maturation Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24183112" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Patency rates of the arteriovenous fistula for hemodialysis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23371955" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cumulative patency of contemporary fistulas versus grafts (2000-2010).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11576369" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of transposed brachiobasilic fistulas to upper arm grafts and brachiocephalic fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26254301" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Early Failure of Dialysis Access among the Elderly in the Era of Fistula First.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23535043" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A systematic review of preoperative duplex ultrasonography and arteriovenous fistula formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11703621" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effect of preoperative sonographic mapping on vascular access outcomes in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35369548" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Patency Outcomes of Arteriovenous Fistulas and Grafts for Hemodialysis Access: A Trade-Off between Nonmaturation and Long-Term Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18945990" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Outcomes of brachiocephalic fistulas, transposed brachiobasilic fistulas, and upper arm grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25063436" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Vascular access choice in incident hemodialysis patients: a decision analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30642607" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Complications From Tunneled Hemodialysis Catheters: A Canadian Observational Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : KDOQI Vascular Access Guidelines Work Group. KDOQI clinical practice guideline for vascular access: 2019 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16813990" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical practice guidelines for hemodialysis adequacy, update 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16497879" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17507428" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : EBPG on Vascular Access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23855977" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : KHA-CARI Guideline: vascular access - central venous catheters, arteriovenous fistulae and arteriovenous grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23813216" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Fistula first is not always the best strategy for the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23431075" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Associations between hemodialysis access type and clinical outcomes: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28143967" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The Effect of Predialysis Fistula Attempt on Risk of All-Cause and Access-Related Death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27605542" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The Survival Benefit of "Fistula First, Catheter Last" in Hemodialysis Is Primarily Due to Patient Factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18155872" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A randomized multicenter study of the outcome of brachial-basilic arteriovenous fistula and prosthetic brachial-antecubital forearm loop as vascular access for hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21803519" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Basilic vein transposition versus biosynthetic prosthesis as vascular access for hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16171591" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Autogenous radial-cephalic or prosthetic brachial-antecubital forearm loop AVF in patients with compromised vessels? A randomized, multicenter study of the patency of primary hemodialysis access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27884849" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : ACCESS HD pilot: A randomised feasibility trial Comparing Catheters with fistulas in Elderly patientS Starting haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35115352" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Optimising Access Surgery in Senior Haemodialysis Patients (OASIS): study protocol for a multicentre randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32891300" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Vessel Preservation in Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18364015" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Guidelines for venous access in patients with chronic kidney disease. A Position Statement from the American Society of Diagnostic and Interventional Nephrology, Clinical Practice Committee and the Association for Vascular Access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19000589" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The Society for Vascular Surgery: clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16988062" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Risk equation determining unsuccessful cannulation events and failure to maturation in arteriovenous fistulas (REDUCE FTM I).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30528400" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Immediate-access grafts provide comparable patency to standard grafts, with fewer reinterventions and catheter-related complications.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
